Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1998 Dec;72(12):10270-4.
doi: 10.1128/JVI.72.12.10270-10274.1998.

Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1

P W Parren  1 , M Wang, A Trkola, J M Binley, M Purtscher, H Katinger, J P Moore, D R Burton
Affiliations
Comparative Study

Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1

P W Parren et al. J Virol. 1998 Dec.

Abstract

Although typical primary isolates of human immunodeficiency virus type 1 (HIV-1) are relatively neutralization resistant, three human monoclonal antibodies and a small number of HIV-1(+) human sera that neutralize the majority of isolates have been described. The monoclonal antibodies (2G12, 2F5, and b12) represent specificities that a putative vaccine should aim to elicit, since in vitro neutralization has been correlated with protection against primary viruses in animal models. Furthermore, a neutralization escape mutant to one of the antibodies (b12) selected in vitro remains sensitive to neutralization by the other two (2G12 and 2F5) (H. Mo, L. Stamatatos, J. E. Ip, C. F. Barbas, P. W. H. I. Parren, D. R. Burton, J. P. Moore, and D. D. Ho, J. Virol. 71:6869-6874, 1997), supporting the notion that eliciting a combination of such specificities would be particularly advantageous. Here, however, we describe a small subset of viruses, mostly pediatric, which show a high level of neutralization resistance to all three human monoclonal antibodies and to two broadly neutralizing sera. Such viruses threaten antibody-based antiviral strategies, and the basis for their resistance should be explored.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Reactivity of soluble gp120 from resistant viruses with MAbs. Infectious culture supernatants were treated with detergent, and gp120 was captured in the well of an ELISA plate coated with sheep anti-gp120 antibody D7324. The reactivities of MAb IgG1 b12 (circles), MAb 2G12 (squares), and control antibody PA-53 (triangles) against HIV-2 envelope protein are shown. As a positive control for the amount of primary gp120 captured, the reactivity of a single 1:5,000 dilution of pooled seropositive human plasma (QC256; diamonds) is plotted on the y axis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Allaway G P, Davis-Bruno K L, Beaudry G A, Garcia E B, Wong E L, Ryder A M, Hasel K W, Gauduin M-C, Koup R A, McDougal J S, Maddon P J. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses. 1995;11:533–539. - PubMed
    1. Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, Purtscher M, Gruber G, Tauer C, Steidl F, Jungbauder A, Katinger H. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses. 1994;10:359–369. - PubMed
    1. Burton D R. A vaccine for HIV type 1: the antibody perspective. Proc Natl Acad Sci USA. 1997;94:10018–10023. - PMC - PubMed
    1. Burton D R, Barbas C F, Persson M A, Koenig S, Chanock R M, Lerner R A. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci USA. 1991;88:10134–10137. - PMC - PubMed
    1. Burton D R, Pyati J, Koduri R, Sharp S J, Thornton G B, Parren P W H I, Sawyer L S W, Hendry R M, Dunlop N, Nara P L, Lamacchia M, Garratty E, Stiehm E R, Bryson Y J, Cao Y, Moore J P, Ho D D, Barbas C F. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 1994;266:1024–1027. - PubMed

Publication types

MeSH terms

LinkOut - more resources